Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Feb 6, 2025	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	383	772	1,519	1,172	1,886	821
Market Cap Growth	-46.07%	-49.18%	29.62%	-37.87%	129.62%	10.32%
Enterprise Value	682	960	1,568	1,224	1,655	642
Last Close Price	3.65	8.79	18.46	16.32	28.34	16.23
PS Ratio	1.37	3.30	11.46	15.06	123.07	1988.80
PB Ratio	-3.34	-5.09	120.54	17.11	5.04	3.64
P/TBV Ratio	-	-	-	-	12.09	3.64
EV/Sales Ratio	2.66	4.10	11.83	15.73	108.00	1555.54
Debt / Equity Ratio	-2.97	-3.16	33.21	4.74	0.57	0.13
Asset Turnover	0.52	0.44	0.24	0.12	0.03	0.00
Inventory Turnover	2.33	4.76	10.74	17.43	-	-
Quick Ratio	2.90	3.16	4.65	3.39	7.19	7.08
Current Ratio	4.12	3.80	4.95	3.66	7.38	7.24
Return on Equity (ROE)	-	-	-879.28%	-127.07%	-94.06%	-85.92%
Return on Assets (ROA)	-24.36%	-26.02%	-30.57%	-27.44%	-31.74%	-36.28%
Return on Capital (ROIC)	-34.49%	-36.40%	-41.29%	-35.06%	-40.01%	-51.34%
Earnings Yield	-48.15%	-41.97%	-23.47%	-24.01%	-14.96%	-19.41%
FCF Yield	-50.88%	-28.95%	-12.96%	-19.79%	-9.68%	-13.32%
Buyback Yield / Dilution	-16.69%	-16.35%	-7.71%	-16.37%	-33.47%	-20.15%
Total Shareholder Return	-16.69%	-16.35%	-7.71%	-16.37%	-33.47%	-20.15%

Source: S&P Capital IQ. Standard template. Financial Sources.